Allergy and Asthma Center of El Paso

Quick facts

Marketed products

• Advair HFA MDI 115/21 · Respiratory/Pulmonology
  Advair HFA combines fluticasone propionate (an inhaled corticosteroid) and salmeterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.
• Symbicort 160/4.5 pMDI · Respiratory/Pulmonology
  Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and dilate airways.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Allergy and Asthma Center of El Paso portfolio CI brief
• Allergy and Asthma Center of El Paso pipeline updates RSS